000			01671 a2200469 4500
005			20250517074903.0
264		0	_c20161111
008			201611s 0 0 eng d
022			_a1531-703X
024	7		_a10.1097/CCO.0000000000000270 _2doi
040			_aNLM _beng _cNLM
100	1		_aGoldinger, Simone M
245	0	0	_aTreatment of melanoma brain metastases. _h[electronic resource]
260			_bCurrent opinion in oncology _cMar 2016
300			_a159-65 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBrain Neoplasms _xmortality
650	0	4	_aCombined Modality Therapy _xmethods
650	0	4	_aDisease-Free Survival
650	0	4	_aHumans
650	0	4	_aImmunotherapy
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aMelanoma _xpathology
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aNivolumab
650	0	4	_aPrognosis
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyridones _xtherapeutic use
650	0	4	_aPyrimidinones _xtherapeutic use
650	0	4	_aQuality of Life
650	0	4	_aSkin Neoplasms _xpathology
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aVemurafenib
700	1		_aPanje, Cédric
700	1		_aNathan, Paul
773	0		_tCurrent opinion in oncology _gvol. 28 _gno. 2 _gp. 159-65
856	4	0	_uhttps://doi.org/10.1097/CCO.0000000000000270 _zAvailable from publisher's website
999			_c25667663 _d25667663